About 16,305 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,309 results

Chemotherapy: how to reduce its adverse effects while maintaining the potency?
Medical Oncology (Northwood, London, England); Brianna , Lee SH

Feb 4th, 2023 - Chemotherapy is one of the widely used anticancer treatments that involves the use of powerful cytotoxic drugs to stop tumor growth by targeting rapidly dividing cells through various mechanisms, which will be elucidated in this review. Introduced...

Autologous Platelet-Rich Plasma Treatment for Androgenic Alopecia: A Systematic Review ...
Plastic and Reconstructive Surgery; Papakonstantinou M, Siotos C et. al.

Feb 3rd, 2023 - Androgenic alopecia (AGA) is a common condition associated with hair loss both in men and women (female pattern hair loss, FPHL), causing considerable psychological distress. Ongoing research focuses on novel safe, cost-effective and efficient tre...

"Efficacy of Platelet-Rich Plasma Plus Basic Fibroblast Growth Factor on the Treatment ...
Plastic and Reconstructive Surgery; Qu Q, He Y et. al.

Feb 3rd, 2023 - Studies have identified platelet-rich plasma (PRP) as a novel adjuvant therapy in AGA. However, the efficacy of PRP still needs to be improved. To assess the efficacy of PRP plus basic fibroblast growth factor (PRPF) for the treatment of AGA. This...

Amelioration of trichotillomania with onabotulinumtoxinA for chronic migraine.
BMJ Case Reports; Engel ER, Ham JA

Feb 3rd, 2023 - We report a case of a woman in her 30s who struggled with a life-long history of trichotillomania (TTM; hair-pulling disorder), which was unsuccessfully treated with behavioural therapy and selective serotonin reuptake inhibitors. In addition to T...

Infantile vitiligo and alopecia in immunodysregulation polyendocrinopathy enteropathy X...
Pediatric Dermatology; Lee WQ, Leong KF

Feb 3rd, 2023 - Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is characterized by failure to thrive, severe chronic diarrhea, neonatal type 1 diabetes or thyroiditis, and eczematous dermatitis. We report a patient with infantile onset IPE...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  471 results see all →

Clinicaltrials.gov  461 results

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Feb 2nd, 2023 - Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-r...

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Feb 2nd, 2023 - The management of Central Centrifugal Cicatricial Alopecia (CCCA) is challenging due to limited current treatments and a lack of randomized controlled trials. Management focuses on behavioral and styling modifications, in addition to symptomatic r...

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Feb 2nd, 2023 - Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege throug...

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Feb 1st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Feb 1st, 2023 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

see more →

News  1,253 results

High Rates of Psychiatric Disorders in Patients With Alopecia Areata

Jan 31st, 2023 - Patients with alopecia areata (AA) had rates of anxiety and depression two to three times higher than the general population, and more than a third had suggestive symptoms, according to a meta-analysis of published data. The results showed a 9% pr...

Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
William Lewis, MD, Amy Forrestel, MD et. al.

Dec 30th, 2022 - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. 1 Symmetrical drug-related intertriginous and fle.

Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
Ivie Obeime, DO, Jorge Larrondo, MD et. al.

Dec 30th, 2022 - With the introduction of the first US Food and Drug Administration (FDA)–approved medication for alopecia areata (AA)—the Janus kinase (JAK) inhibitor, baricitinib—there is an important focus on this disease in the literature and for practicing de.

Study evaluates features of alopecia areata in Hispanic/Latinx patients
Doug Brunk

Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.

5-ARIs Not Linked to Risk of Dementia Over the Long Term

Dec 22nd, 2022 - Men taking 5α-reductase inhibitors (5-ARIs), commonly used for androgenic alopecia and benign prostatic hyperplasia (BPH), should be aware of possible adverse psychological effects, researchers warned. In a register-based cohort study of over 2.2 ...

see more →

Patient Education  25 results see all →